CA2411153A1 - Method for preparing a composition - Google Patents

Method for preparing a composition

Info

Publication number
CA2411153A1
CA2411153A1 CA002411153A CA2411153A CA2411153A1 CA 2411153 A1 CA2411153 A1 CA 2411153A1 CA 002411153 A CA002411153 A CA 002411153A CA 2411153 A CA2411153 A CA 2411153A CA 2411153 A1 CA2411153 A1 CA 2411153A1
Authority
CA
Canada
Prior art keywords
compositions
preparing
solution
homogeneous dispersion
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002411153A
Other languages
French (fr)
Other versions
CA2411153C (en
Inventor
Patrick Busson
Marco Schroeder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cheplapharm Arzneimittel GmbH
Original Assignee
Patrick Busson
Marco Schroeder
F. Hoffmann-La Roche Ag
Cheplapharm Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2411153(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Patrick Busson, Marco Schroeder, F. Hoffmann-La Roche Ag, Cheplapharm Arzneimittel Gmbh filed Critical Patrick Busson
Publication of CA2411153A1 publication Critical patent/CA2411153A1/en
Application granted granted Critical
Publication of CA2411153C publication Critical patent/CA2411153C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a method for the preparation of compositions, preferably pharmaceutical compositions, in form of expanded, mechanically stable, lamellar, porous, spongue-like or foam structures out of solutions and dispersions. This method comprises the steps of a) preparing a solution or a homogeneous dispersion of a liquid and a compound selected from the group consisting of one or more pharmaceutically active compounds, one or more pharmaceutically suitable excipients, and mixtures thereof, followed by b) the expansion of the solution or the homogeneous dispersion without boiling. The invention also relates to the compositions, their further processing and any corresponding dosage forms obtainable by the above method.
CA002411153A 2000-06-27 2001-06-18 Method for preparing a composition Expired - Lifetime CA2411153C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00113535.9 2000-06-27
EP00113535 2000-06-27
PCT/EP2001/006834 WO2002000201A2 (en) 2000-06-27 2001-06-18 Method for preparing a composition

Publications (2)

Publication Number Publication Date
CA2411153A1 true CA2411153A1 (en) 2002-01-03
CA2411153C CA2411153C (en) 2007-01-30

Family

ID=8169074

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002411153A Expired - Lifetime CA2411153C (en) 2000-06-27 2001-06-18 Method for preparing a composition

Country Status (38)

Country Link
US (3) US6534087B2 (en)
EP (1) EP1296656B1 (en)
JP (2) JP4149803B2 (en)
KR (1) KR100557845B1 (en)
CN (1) CN1236764C (en)
AR (1) AR029278A1 (en)
AT (1) ATE334662T1 (en)
AU (2) AU2001281846B2 (en)
BR (1) BRPI0112014B1 (en)
CA (1) CA2411153C (en)
CY (1) CY1105714T1 (en)
CZ (1) CZ301813B6 (en)
DE (1) DE60121953T2 (en)
DK (1) DK1296656T3 (en)
EC (1) ECSP024401A (en)
EG (1) EG24141A (en)
ES (1) ES2269441T3 (en)
HK (1) HK1058314A1 (en)
HR (1) HRP20021009B1 (en)
HU (1) HU229550B1 (en)
IL (2) IL153282A0 (en)
JO (1) JO2247B1 (en)
MA (1) MA26922A1 (en)
ME (1) MEP90608A (en)
MX (1) MXPA02012583A (en)
MY (1) MY129798A (en)
NO (1) NO332181B1 (en)
NZ (1) NZ523024A (en)
PE (1) PE20020101A1 (en)
PL (1) PL203804B1 (en)
PT (1) PT1296656E (en)
RU (1) RU2244542C2 (en)
SI (1) SI1296656T1 (en)
TW (1) TWI278325B (en)
UY (1) UY26799A1 (en)
WO (1) WO2002000201A2 (en)
YU (1) YU96602A (en)
ZA (1) ZA200209649B (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
DE60121953T2 (en) * 2000-06-27 2007-03-08 F. Hoffmann-La Roche Ag METHOD OF MANUFACTURING MEDICINE PREPARATIONS
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
MY135783A (en) * 2001-09-07 2008-06-30 Meiji Dairies Corp Nutritional composition for controlling blood sugar level
CA2483002C (en) * 2002-04-26 2011-02-01 F. Hoffmann-La Roche Ag New pharmaceutical composition
KR100517072B1 (en) * 2002-11-25 2005-09-26 주식회사 태평양 Polyol/polymer microcapsule and the stabilization method of enzyme using it
US9174176B2 (en) * 2003-01-09 2015-11-03 Disperse Systems, Inc. Ultrasonic dispersion apparatus, system, and method
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
US8030362B2 (en) * 2003-12-12 2011-10-04 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
AU2005244329A1 (en) * 2004-04-06 2005-11-24 Rpg Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
JP4329816B2 (en) * 2004-09-15 2009-09-09 萬有製薬株式会社 Sampling method, sampling device, logD measuring method and logD measuring system
WO2006073333A2 (en) * 2004-12-31 2006-07-13 Mikhail Yurievich Gotovsky Magnetoresonance preparations, device for individually selecting said preparations for increasing an organism life activity in actual environmental conditions
US20060198856A1 (en) * 2005-03-01 2006-09-07 Keith Whitehead Ibuprofen suspension stabilized with docusate sodium
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US7984717B2 (en) * 2005-04-29 2011-07-26 Medtronic, Inc. Devices for augmentation of lumen walls
WO2006138431A2 (en) * 2005-06-16 2006-12-28 Eastman Chemical Company Methods and pharmaceutical formulations for increasing bioavailability
WO2006136197A1 (en) 2005-06-21 2006-12-28 V. Mane Fils Smoking device incorporating a breakable capsule, breakable capsule and process for manufacturing said capsule
US20070048364A1 (en) * 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
KR100669497B1 (en) * 2005-08-17 2007-01-16 보람제약주식회사 Pharmaceutical formulation with high stability and dissolution and manufacturing method
AR056499A1 (en) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd COMPOUNDS
CN101340884A (en) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 Methods for the treatment of hyperhidrosis
ES2470340T3 (en) 2005-12-28 2014-06-23 Advanced Bionutrition Corporation Administration vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in vitreous form
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
FR2895908B1 (en) * 2006-01-12 2008-03-28 France Etat PROCESS FOR MAKING A PHARMACEUTICAL FORM OF OSELTAMIVIR PHOSPHATE
EP1987825B1 (en) 2006-02-20 2018-09-05 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
US7903256B2 (en) 2006-03-16 2011-03-08 Duke University Methods, systems, and computer program products for performing real-time quadrature projection based Fourier domain optical coherence tomography
CN1820744B (en) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 Oseltamivir phosphate granula and its preparing method
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
KR100812824B1 (en) 2006-09-27 2008-03-12 주식회사 제닉 Biocompatible low toxicity film using chitosan and polyethylene glycol
JP5285617B2 (en) 2006-12-18 2013-09-11 アドバンスド バイオニュートリション コーポレーション Dry food products containing live probiotics
JP5489988B2 (en) * 2007-05-18 2014-05-14 Ｔｔｉ・エルビュー株式会社 Transdermal delivery device ensuring improved release of active ingredients to the biological interface
KR101439470B1 (en) * 2007-05-22 2014-09-16 한미사이언스 주식회사 Composition comprising orlistat and a stool softner for preventing or treating obesity
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (en) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Production method of a stable Orlistat composition in form of encapsulated powder
GB0900551D0 (en) * 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
EP3266448B1 (en) 2009-03-27 2022-02-16 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
CN102459568A (en) 2009-05-26 2012-05-16 先进生物营养公司 Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
EP2482802A4 (en) * 2009-09-29 2013-08-07 Michael Burnet Novel pesticide formulations
KR100940745B1 (en) * 2009-10-15 2010-02-04 광동제약 주식회사 Coated pellet containing orlistat and attapulgite and its preparation formulation
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
RU2535869C2 (en) 2010-01-28 2014-12-20 Эдванст Бионутришн Корпорейшн Dry glass-like composition for stabilisation and protection of biologically active material, and method for its obtaining
KR101021030B1 (en) * 2010-03-25 2011-03-09 엘지이노텍 주식회사 Phosphor coating method, method of fabricating light emitting apparatus, and coated phosphor
JP5974891B2 (en) * 2010-04-07 2016-08-23 三菱瓦斯化学株式会社 S-adenosyl-L-methionine-containing dry yeast composition having excellent storage stability and method for producing the same
MX350047B (en) 2010-08-13 2017-08-24 Advanced Bionutrition Corp Dry storage stabilizing composition for biological materials.
AU2011320159B2 (en) * 2010-10-29 2016-12-22 Western University Of Health Sciences Ternary mixture formulations
WO2012125297A1 (en) 2011-03-01 2012-09-20 The Procter & Gamble Company Porous disintegratable solid substrate for personal health care applications
MX356072B (en) 2012-03-23 2018-05-14 Advanced Bionutrition Corp Stabilizing composition for biological materials.
CN103222964B (en) * 2013-01-29 2014-10-08 青岛大学 Orlistat oral preparation and preparation method thereof
GB2524496A (en) * 2014-03-24 2015-09-30 British Airways Plc Dynamic tracking and control of passenger travel progress
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
CN107849597B (en) 2015-06-25 2022-07-26 原生微生物股份有限公司 Method for forming a population of active microbial strains based on analysis of heterogeneous microbial communities
ES2881809T3 (en) 2015-07-29 2021-11-30 Advanced Bionutrition Corp Stable dry probiotic compositions for special dietary uses
JP6778051B2 (en) * 2016-08-18 2020-10-28 沢井製薬株式会社 Oseltamivir phosphate-containing pharmaceutical composition
US11891647B2 (en) 2016-12-28 2024-02-06 Native Microbials, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
WO2019069108A1 (en) * 2017-10-04 2019-04-11 Debreceni Egyetem Prolonged-release, gastroretentive, moulded, solid dosage form and process for the preparation thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (en) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 New physiologically active substance esterastin and its production method
US4489438A (en) * 1982-02-01 1984-12-18 National Data Corporation Audio response system
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
JP3069458B2 (en) 1992-01-29 2000-07-24 武田薬品工業株式会社 Orally disintegrating tablet and production method thereof
US5560921A (en) 1992-06-01 1996-10-01 The Procter & Gamble Company Chewable decongestant compositions
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
WO1994018951A1 (en) * 1993-02-23 1994-09-01 Warner-Lambert Company A process for the preparation of substantially alcohol free pharmaceutical compositions
DE4317320A1 (en) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh New thiazolidinediones and medicines containing them
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5536264A (en) * 1993-10-22 1996-07-16 The Procter & Gamble Company Absorbent composites comprising a porous macrostructure of absorbent gelling particles and a substrate
US5523106A (en) * 1994-02-03 1996-06-04 Nabisco, Inc. Juice-based expanded snacks and process for preparing them
HU229200B1 (en) 1995-02-27 2013-09-30 Gilead Sciences Inc Selective inhibitors of viral or bacterial neuraminidase
SI9620042A (en) 1995-02-27 1998-12-31 Gilead Sciences, Inc. Novel selective inhibitors of viral or bacterial neuraminidases
SK167597A3 (en) * 1995-06-07 1998-10-07 Quadrant Holdings Cambridge Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
US5763483A (en) 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
ES2217410T3 (en) * 1996-04-16 2004-11-01 Novartis Consumer Health S.A. ORAL DOSAGE FORM OF FAST DISINTEGRATION.
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
CN1233169A (en) * 1996-10-14 1999-10-27 弗·哈夫曼-拉罗切有限公司 Process for the manufacture of a pulverous preparation
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
JPH11137208A (en) 1997-11-14 1999-05-25 Nikken Chem Co Ltd Solid material rapidly soluble in oral cavity and its production
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
WO1999052504A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
PT1105122E (en) 1998-08-14 2005-08-31 Hoffmann La Roche PHARMACEUTICAL COMPOSITIONS CONTAINING LIPASE INHIBITORS
DE69916288T2 (en) * 1998-08-14 2005-03-24 F. Hoffmann-La Roche Ag LIPASE-HEMMER AND CHITOSAN-CONTAINING MEDICINAL PRODUCTS
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE60039379D1 (en) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmaceutical solid dispersions
GB9904629D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Oral drug delivery system
FR2791569B1 (en) * 1999-03-31 2003-05-09 Pf Medicament ISOTROPIC FAST DISSOLVING ISOTROPIC MICROPOROUS COMPOSITION OR STRUCTURE FOR PHARMACEUTICAL, VETERINARY, DIETETIC, FOOD OR COSMETIC USE AND PROCESS FOR OBTAINING THE SAME
DE60121953T2 (en) * 2000-06-27 2007-03-08 F. Hoffmann-La Roche Ag METHOD OF MANUFACTURING MEDICINE PREPARATIONS

Also Published As

Publication number Publication date
US20060134205A1 (en) 2006-06-22
CN1438880A (en) 2003-08-27
KR20030023880A (en) 2003-03-20
TWI278325B (en) 2007-04-11
EP1296656A2 (en) 2003-04-02
AR029278A1 (en) 2003-06-18
ES2269441T3 (en) 2007-04-01
JO2247B1 (en) 2004-10-07
CY1105714T1 (en) 2010-12-22
MXPA02012583A (en) 2003-04-10
PL203804B1 (en) 2009-11-30
ME00672B (en) 2011-12-20
MY129798A (en) 2007-04-30
RU2244542C2 (en) 2005-01-20
PE20020101A1 (en) 2002-02-12
YU96602A (en) 2005-03-15
WO2002000201A2 (en) 2002-01-03
US20030039614A1 (en) 2003-02-27
UY26799A1 (en) 2001-12-28
BR0112014A (en) 2003-05-13
US6534087B2 (en) 2003-03-18
ZA200209649B (en) 2004-03-10
EG24141A (en) 2008-08-06
US20020018812A1 (en) 2002-02-14
HUP0302060A2 (en) 2003-09-29
US7074431B2 (en) 2006-07-11
DK1296656T3 (en) 2006-11-27
HK1058314A1 (en) 2004-05-14
MEP90608A (en) 2011-12-20
PL365803A1 (en) 2005-01-10
PT1296656E (en) 2006-12-29
HU229550B1 (en) 2014-01-28
NZ523024A (en) 2004-08-27
KR100557845B1 (en) 2006-03-10
MA26922A1 (en) 2004-12-20
HUP0302060A3 (en) 2006-07-28
DE60121953T2 (en) 2007-03-08
SI1296656T1 (en) 2006-12-31
BRPI0112014B1 (en) 2016-09-13
WO2002000201A3 (en) 2002-04-18
DE60121953D1 (en) 2006-09-14
HRP20021009B1 (en) 2011-07-31
CN1236764C (en) 2006-01-18
IL153282A (en) 2008-03-20
CZ2003212A3 (en) 2003-06-18
AU8184601A (en) 2002-01-08
EP1296656B1 (en) 2006-08-02
NO332181B1 (en) 2012-07-16
JP4149803B2 (en) 2008-09-17
ATE334662T1 (en) 2006-08-15
NO20026197L (en) 2002-12-23
HRP20021009A2 (en) 2004-02-29
IL153282A0 (en) 2003-07-06
JP2004501184A (en) 2004-01-15
CZ301813B6 (en) 2010-06-30
CA2411153C (en) 2007-01-30
ECSP024401A (en) 2003-02-06
AU2001281846B2 (en) 2006-04-27
JP2007302683A (en) 2007-11-22
NO20026197D0 (en) 2002-12-23

Similar Documents

Publication Publication Date Title
CA2411153A1 (en) Method for preparing a composition
WO2001089479A3 (en) Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
CA2402431A1 (en) 1,2,3,4-tetrahydroisoquinoline derivatives
DK0831770T3 (en) Continuous fluorochemical microdispersions for delivery of pharmaceutical agents
CA2317106A1 (en) Method and composition of an oral preparation of itraconazole
RU96118271A (en) COMPOSITIONS CONTAINING FINE-CREATED NEBIVOL
DK0973506T3 (en) Process for the preparation of solid pharmaceutical dosage forms
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
CA2361402A1 (en) Bis-sulfonamides
EP0992509A3 (en) Novel macrolide derivatives
IL162496A0 (en) Pharmaceutical compositions containing cyclosporin
CA2063273A1 (en) Surfactant compositions and methods
CA2502582A1 (en) Pharmaceutical formulation of olanzapine
AU2001239625A1 (en) Method of preparing solid dispersions
WO2003035043A3 (en) Pharmaceutical formulation comprising more than 15% tamoxifen
WO2002038133A3 (en) Compositions containing hydrolytically unstable compounds
MX231185B (en) Process for the preparation of pharmaceutical compositions in the form of rapidly desintegrating tablets, which are substantially free of the pharmacologically active principle from the agent crystalline structure modification during the manufacturin
CA2066945A1 (en) Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam
TH32548B (en) Composition with micronized nebiVolol

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210618